Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gptkb:granulocyte_colony-stimulating_factor |
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA 2002 |
| gptkbp:ATCCode |
L03AA13
|
| gptkbp:biosimilar |
yes
|
| gptkbp:brand |
gptkb:Neulasta
|
| gptkbp:CASNumber |
208265-92-3
|
| gptkbp:chemicalClass |
pegylated protein
|
| gptkbp:contraindication |
hypersensitivity to pegfilgrastim
|
| gptkbp:developedBy |
gptkb:Amgen
|
| gptkbp:eliminationHalfLife |
15-80 hours
|
| gptkbp:hasMolecularFormula |
C845H1343N223O243S9
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
stimulates production of neutrophils
|
| gptkbp:pegylated |
yes
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:product |
recombinant human G-CSF
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:sideEffect |
bone pain
allergic reactions splenic rupture |
| gptkbp:UNII |
6X8X110A8H
|
| gptkbp:usedFor |
chemotherapy-induced neutropenia
prevention of neutropenia |
| gptkbp:bfsParent |
gptkb:Neulasta
|
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
pegfilgrastim
|